Merck KGaA Selects Nippon Shinyaku as Japanese Partner For Alcohol Addiction Treatment
The agreement covers the development, marketing and promotion of acamprosate in Japan by Nippon Shinyaku. It includes milestone payments at key development stages as well as royalties on future sales by Nippon Shinyaku, along with an exclusive supply of acamprosate by Merck.
"Merck is very pleased to conclude this partnership agreement for acamprosate in Japan with Nippon Shinyaku," said Wilfried H. Meyer, Head of Merck KGaA's Established Products business.
Acamprosate has been approved in most major European markets for several years and is commercialized under the brand names Campral® and Aotal®. In addition, acamprosate is currently under registration in the US, and Merck will file an amendment to the New Drug Application with the U.S. Food and Drug Administration (FDA) later this year. "In this context, the collaboration with Nippon Shinyaku represents a key step in our global marketing strategy," Meyer added.
Other news from the department business & finance
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.